Nextage Therapeutics Ltd
Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomark… Read more
Nextage Therapeutics Ltd (MCTC) - Net Assets
Latest net assets as of June 2020: ILA1.99 Million ILA
Based on the latest financial reports, Nextage Therapeutics Ltd (MCTC) has net assets worth ILA1.99 Million ILA as of June 2020.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA4.90 Million) and total liabilities (ILA2.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA1.99 Million |
| % of Total Assets | 40.54% |
| Annual Growth Rate | -6.54% |
| 5-Year Change | -27.7% |
| 10-Year Change | -74.74% |
| Growth Volatility | 62.32 |
Nextage Therapeutics Ltd - Net Assets Trend (2002–2019)
This chart illustrates how Nextage Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nextage Therapeutics Ltd (2002–2019)
The table below shows the annual net assets of Nextage Therapeutics Ltd from 2002 to 2019.
| Year | Net Assets | Change |
|---|---|---|
| 2019-12-31 | ILA3.66 Million | +321.71% |
| 2018-12-31 | ILA-1.65 Million | -137.16% |
| 2017-12-31 | ILA4.44 Million | +87.93% |
| 2016-12-31 | ILA2.36 Million | -53.31% |
| 2015-12-31 | ILA5.06 Million | -34.24% |
| 2014-12-31 | ILA7.69 Million | -63.92% |
| 2013-12-31 | ILA21.32 Million | +43.11% |
| 2012-12-31 | ILA14.89 Million | -11.00% |
| 2011-12-31 | ILA16.73 Million | +15.64% |
| 2010-12-31 | ILA14.47 Million | +89.18% |
| 2009-12-31 | ILA7.65 Million | +27.16% |
| 2008-12-31 | ILA6.02 Million | -14.75% |
| 2003-12-31 | ILA7.06 Million | -38.82% |
| 2002-12-31 | ILA11.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nextage Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12230000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2019)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA126.00 Million | 3403.62% |
| Total Equity | ILA3.70 Million | 100.00% |
Nextage Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Nextage Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PZ Cussons PLC
LSE:PZC
|
$45.16K |
|
DIVIDEND 15 SPLIT A CD 15
F:641
|
$45.21K |
|
DaikyoNishikawa Corp
F:DK8
|
$45.22K |
|
HGCAPITAL TRUST LS-025
F:5AC
|
$45.23K |
|
NGRD3F
SA:NGRD3F
|
$45.04K |
|
Dividend Select 15 Corp
PINK:DVVDF
|
$45.02K |
|
Bowen Acquisition Corp Rights
NASDAQ:BOWNR
|
$44.98K |
|
PFERDEWETTEN AG
STU:EMH1
|
$44.95K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nextage Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2018 to 2019, total equity changed from -1,625,000 to 3,702,000, a change of 5,327,000.
- Net loss of 2,088,000 reduced equity.
- Other factors increased equity by 7,415,000.
Equity Change Factors (2018 to 2019)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-2.09 Million | -56.4% |
| Other Changes | ILA7.42 Million | +200.3% |
| Total Change | ILA- | % |
Book Value vs Market Value Analysis
This analysis compares Nextage Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Nextage Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -56.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -703.03%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.62x
- Recent ROE (-56.40%) is above the historical average (-145.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -57.10% | -36224.14% | 0.00x | 1.62x | ILA-12.34 Million |
| 2014 | -203.04% | -12227.35% | 0.01x | 2.41x | ILA-15.01 Million |
| 2015 | -201.57% | 0.00% | 0.00x | 2.64x | ILA-10.53 Million |
| 2016 | -373.92% | -31235.71% | 0.00x | 4.88x | ILA-8.98 Million |
| 2017 | -128.78% | -1415.31% | 0.03x | 2.78x | ILA-6.18 Million |
| 2018 | 0.00% | -2280.68% | 0.07x | 0.00x | ILA-8.57 Million |
| 2019 | -56.40% | -703.03% | 0.05x | 1.62x | ILA-2.46 Million |
Industry Comparison
This section compares Nextage Therapeutics Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
No peer company data available for comparison.